CardieX
Market Cap
AU$61.0m
Last Updated
2021/04/11 08:17 UTC
Data Sources
Company Financials
Executive Summary
CardieX Limited designs, manufactures, and markets medical devices for use in cardiovascular health management in the Americas, Europe, and the Asia Pacific. More Details
Rewards
Risk Analysis
Snowflake Analysis
Excellent balance sheet with weak fundamentals.
Share Price & News
How has CardieX's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CDX is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: CDX's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Australian stocks.
Market Performance
7 Day Return
-4.3%
CDX
2.4%
AU Medical Equipment
2.6%
AU Market
1 Year Return
214.3%
CDX
22.0%
AU Medical Equipment
37.1%
AU Market
Return vs Industry: CDX exceeded the Australian Medical Equipment industry which returned 22% over the past year.
Return vs Market: CDX exceeded the Australian Market which returned 37.1% over the past year.
Shareholder returns
| CDX | Industry | Market | |
|---|---|---|---|
| 7 Day | -4.3% | 2.4% | 2.6% |
| 30 Day | 0% | 6.9% | 4.4% |
| 90 Day | -17.5% | 4.8% | 3.6% |
| 1 Year | 214.3%214.3% | 23.1%22.0% | 41.3%37.1% |
| 3 Year | 208.6%200.0% | 33.8%28.0% | 36.2%19.8% |
| 5 Year | -57.6%-58.8% | 89.7%76.9% | 67.4%34.6% |
Long-Term Price Volatility Vs. Market
How volatile is CardieX's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
What Can We Learn About CardieX's (ASX:CDX) CEO Compensation?2 months ago | Simply Wall St
Shareholders Are Thrilled That The CardieX (ASX:CDX) Share Price Increased 169%4 months ago | Simply Wall St
Have Insiders Been Buying CardieX Limited (ASX:CDX) Shares?Valuation
Is CardieX undervalued compared to its fair value and its price relative to the market?
7.96x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CDX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CDX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CDX is unprofitable, so we can't compare its PE Ratio to the AU Medical Equipment industry average.
PE vs Market: CDX is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CDX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CDX is overvalued based on its PB Ratio (8x) compared to the AU Medical Equipment industry average (6.6x).
Future Growth
How is CardieX forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
21.8%
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as CardieX has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has CardieX performed over the past 5 years?
7.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CDX is currently unprofitable.
Growing Profit Margin: CDX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CDX is unprofitable, but has reduced losses over the past 5 years at a rate of 7.2% per year.
Accelerating Growth: Unable to compare CDX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CDX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (31.7%).
Return on Equity
High ROE: CDX has a negative Return on Equity (-48.23%), as it is currently unprofitable.
Financial Health
How is CardieX's financial position?
Financial Position Analysis
Short Term Liabilities: CDX's short term assets (A$6.1M) exceed its short term liabilities (A$3.6M).
Long Term Liabilities: CDX's short term assets (A$6.1M) exceed its long term liabilities (A$121.8K).
Debt to Equity History and Analysis
Debt Level: CDX's debt to equity ratio (20.6%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if CDX's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CDX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CDX has sufficient cash runway for 1.8 years if free cash flow continues to grow at historical rates of 9.3% each year.
Dividend
What is CardieX current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CDX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CDX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CDX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CDX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CDX's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.3yrs
Average management tenure
CEO
Craig Cooper
3.33yrs
Tenure
AU$911,125
Compensation
Mr. Craig R. Cooper is the Co-Owner at C2 Ventures Pty Ltd. Mr. Cooper has been Chief Executive Officer, Managing Director and Executive Director at CardieX Limited (formerly known as AtCor Medical Holding...
CEO Compensation Analysis
Compensation vs Market: Craig's total compensation ($USD694.56K) is above average for companies of similar size in the Australian market ($USD285.87K).
Compensation vs Earnings: Craig's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: CDX's management team is considered experienced (2.3 years average tenure).
Board Members
Experienced Board: CDX's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CDX insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 22.7%.
Top Shareholders
Company Information
CardieX Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: CardieX Limited
- Ticker: CDX
- Exchange: ASX
- Founded: 1994
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: AU$61.011m
- Shares outstanding: 924.41m
- Website: https://cardiex.com
Location
- CardieX Limited
- 15 Lime Street
- Suite 303
- Sydney
- New South Wales
- 2000
- Australia
Listings
Biography
CardieX Limited designs, manufactures, and markets medical devices for use in cardiovascular health management in the Americas, Europe, and the Asia Pacific. The company develops, markets, and distributes ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/04/11 08:17 |
| End of Day Share Price | 2021/04/09 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.